Octamoxin: Difference between revisions
CSV import |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 25: | Line 25: | ||
{{stub}} | {{stub}} | ||
== Octamoxin == | |||
<gallery> | |||
File:Octamoxin_skeletal.svg|Octamoxin skeletal structure | |||
</gallery> | |||
Latest revision as of 00:47, 17 March 2025
Octamoxin is an monoamine oxidase inhibitor (MAOI) that was developed in the 1960s for the treatment of depression. It is a non-selective and irreversible inhibitor of the enzyme monoamine oxidase (MAO).
Etymology[edit]
The term "Octamoxin" is derived from the chemical structure of the compound, which contains eight carbon atoms (from the Latin octo, meaning "eight") and an amine group (from the Arabic al-'anmā, meaning "the bleach").
Pharmacology[edit]
Octamoxin works by inhibiting the action of monoamine oxidase, an enzyme that breaks down monoamines in the body. By inhibiting this enzyme, Octamoxin increases the levels of monoamines such as serotonin, norepinephrine, and dopamine in the brain, which can help to alleviate symptoms of depression.
Clinical Use[edit]
Octamoxin was used in the 1960s as a treatment for depression. However, it has largely been replaced by newer and safer MAOIs due to its potential for serious side effects and interactions with other drugs.
Side Effects[edit]
The side effects of Octamoxin can include hypertension, insomnia, dizziness, and nausea. In rare cases, it can also cause a serious condition known as serotonin syndrome, which can be life-threatening if not treated promptly.
